IntelGenx Technologies Corp. IGXT
Set alert
0.17 +0.17 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 29.69M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
More statistics
- Low
- —
- High
- —
- Earnings
- Dec 26, 2024
Next earnings
Dec 26, 2024
Expected Dec 26, 2024. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 26, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Sep 30, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -0.02 | — | — |
| Mar 21, 2024 | Dec 1, 2023 | 0.00 | -0.02 | — | — |
| Nov 9, 2023 | Sep 1, 2023 | 0.00 | -0.01 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -0.02 | — | — |
News
- IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG
- IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation Process
- IntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA' Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer's Disease
- IntelGenx Announces Initiation of the Sale and Investment Solicitation Process
- IntelGenx Obtains Court-Approval of a Sale and Investment Solicitation Process
- IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives
- IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives
- IntelGenx Announces Voting Results on Election of Directors
- IntelGenx Announces First Parkinson's Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK' Clinical Trial
- IntelGenx Updates Status of Buprenorphine Buccal Film ANDA
Your note
Sign in to keep a note on IGXT — it syncs with the Stock Master app.